

Bod Science establishes R&D funding facility

- Radium Capital will advance \$437,598.00 to Bod representing the expected R&D (Research and Development) tax incentive for H1 FY23, based on Bod's domestic R&D spend
- The loan facility provides early access to a portion of Bod's FY23 R&D tax rebate

Sydney, Australia – 6 March 2023: Cannabis focused drug development and product innovation company Bod Science Limited ("**Bod**" or "**the Company**") (ASX: **BOD**) is pleased to advise the establishment of a loan facility with Radium Capital.

Radium Capital ("Radium") is a Research and Development (R&D) finance provider offering strategic capital by way of early access to R&D refunds secured against the ATO rebate, reducing the need for dilutionary equity. Radium Capital will loan an amount equal to 80% of the R&D tax incentive based on eligible spend for a specified period.

For H1 FY23, Radium will loan Bod an amount of \$437,598.00 representing 80% of the expected R&D tax incentive for H1 FY23, based on Bod's domestic R&D spend. The loan is secured by a featherweight security agreement over the FY23 R&D tax rebate from the ATO, at an annual interest rate of 16% and repayable 31st December 2023. The loan may be extended by 30 days on two separate occasions at the discretion of the lender if, against expectation, there are delays in the receipt of the rebate from the ATO.

This announcement has been approved by the Board of Bod Science Limited.

-ENDS-

About Bod Science:

Bod Science (ASX:BOD) is a cannabis focused drug development and product innovation company.

Bod is focused on progressing research and development with a defined clinical trial pathway to commercialise and deliver premium, scientifically proven and trusted products for patients and consumers.

The company has a number of existing partnerships with large corporate companies and collaborations with leading research organisations to advance the use of Cannabis related medicines with therapeutic indications.

For more information please contact:

Jo Patterson Chief Executive Officer Info@bodaustralia.com +61 2 9199 5018 Amalie Schreurs White Noise Communications amalie@whitenoisecomms.com +61 431 636 033

CONTACT

T +61 2 9199 5018 E info@bodaustralia.com ASX:BOD bodscience.com

